Press Releases

07/25/23

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
07/17/23

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
06/06/23

Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
05/02/23

Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
05/01/23

Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
02/28/23

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
02/27/23

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
01/09/23

Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
01/03/23

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
11/30/22

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
11/23/22

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
11/01/22

Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10/31/22

Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
09/12/22

Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
08/03/22

Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
08/03/22

Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08/03/22

Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
08/02/22

Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
05/03/22

Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
05/02/22

Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
02/22/22

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
02/22/22

Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
02/18/22

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
01/10/22

Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones
01/03/22

Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
12/28/21

Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
11/23/21

Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
11/01/21

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
10/29/21

Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
09/21/21

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
08/16/21

Kiniksa Announces Launch of ARCALYST Named Patient Program
08/03/21

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
08/02/21

Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
07/20/21

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
06/08/21

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
06/08/21

Kiniksa Outlines Next Steps for the Development of Mavrilimumab
06/01/21

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
05/04/21

Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
05/04/21

Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
04/12/21

Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
04/01/21

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
03/18/21

Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
03/02/21

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
02/23/21

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
01/11/21

Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
01/04/21

Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
12/22/20

Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
12/15/20

Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
11/30/20

Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
11/24/20

Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
11/23/20

Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
11/17/20

Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
11/16/20

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
11/09/20

Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
11/05/20

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
10/29/20

Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis Presented at European Academy of Dermatology and Venereology Virtual Congress
10/26/20

Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
10/06/20

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
09/24/20

Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
09/21/20

Kiniksa Announces Upcoming Rilonacept Analyst Day
09/15/20

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
09/09/20

Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
08/31/20

Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
08/04/20

Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
07/30/20

Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
07/21/20

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
07/20/20

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
07/16/20

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
06/29/20

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
06/17/20

Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
06/10/20

Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
06/08/20

Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
06/04/20

Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
05/29/20

Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
05/18/20

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/13/20

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
05/13/20

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
05/11/20

Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
04/28/20

Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
04/22/20

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
03/31/20

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
03/30/20

Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
02/26/20

Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
01/13/20

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
12/11/19

Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
12/10/19

Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
11/20/19

Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
11/20/19

Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
11/16/19

Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
11/12/19

Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
10/28/19

Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
09/19/19

Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research
08/19/19

Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
08/12/19

Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
08/12/19

Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial
08/06/19

Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference
08/05/19

Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community
06/12/19

Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology
05/30/19

Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
05/29/19

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
05/16/19

Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research
05/13/19

Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
05/02/19

Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
04/17/19

Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
04/08/19

Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
03/18/19

Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
03/07/19

Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
02/28/19

Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
02/26/19

Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference
01/31/19

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
01/28/19

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement
01/03/19

Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
12/17/18

Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
12/11/18

Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
12/06/18

Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis
11/01/18

Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress
09/15/18

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
08/29/18

Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
08/28/18

Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference
08/06/18

Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress
08/02/18

Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference
06/25/18

Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares
06/14/18

Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference
05/29/18

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering
05/23/18

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering
12/21/17

Kiniksa Pharmaceuticals to Present at 36th Annual J.P. Morgan Healthcare Conference
12/20/16

Sanj K. Patel to Introduce Kiniksa Pharmaceuticals at 35th Annual J.P. Morgan Healthcare Conference

Print Page

RSS

Email Alerts

Search

Here for you, every second

Locations

Press Releases